Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec;28(12):3119-26.
doi: 10.1093/ndt/gft298. Epub 2013 Sep 30.

HLA-A2, HLA-B44 and HLA-DR15 are associated with lower risk of BK viremia

Affiliations

HLA-A2, HLA-B44 and HLA-DR15 are associated with lower risk of BK viremia

Kosuke Masutani et al. Nephrol Dial Transplant. 2013 Dec.

Abstract

Background: Human leucocyte antigens (HLAs) modulate immunity to polyomavirus BK (BKV). Identification of HLAs that alter the course of infection will facilitate risk stratification, and customization of pre-emptive intervention strategies.

Methods: We performed a retrospective cohort study with 998 kidney transplant patients with BKV infection status confirmed by polymerase chain reaction (PCR). Clinical parameters and donor-recipient matching for specific HLAs were examined in relation to occurrence of viremia. An emphasis was placed on donor-recipient matching rather than the actual frequency of specific HLA-alleles, since a successful immune response requires sharing of HLAs between a virus-infected target cell and the anti-viral effector cell.

Results: Using multivariate statistics, low risk of BK viremia was associated with matching of HLA-A2 [hazard ratio (HR) 0.51, 95% confidence interval (CI) 0.28-0.85], HLA-B44 (HR 0.31, 95% CI 0.076-0.85) and HLA-DR15 (HR 0.35, 95% CI 0.084-0.93) (P < 0.05), whereas high risk of viremia was associated with male gender (HR 2.38, 95% CI 1.46-4.09, P < 0.001).

Conclusions: HLAs that associated with a lower predisposition to the development of BK viremia have been identified. Evaluation of donor-recipient mismatching for these HLAs could potentially be used to (i) fine tune virus screening strategies for BKV in individual patients and (ii) facilitate discovery of major histocompatibility complex (MHC) class I and II binding peptides that can elicit clinically meaningful BKV-specific immunity.

Keywords: HLA mismatch; genotype; polymerase chain reaction (PCR); screening; viremia.

PubMed Disclaimer

Figures

FIGURE 1:
FIGURE 1:
Cumlative incidence of BK viremia in donor and recipient combinations with matching for the specified HLA. The P-values as indicated have been calculated by the log-rank test.

Similar articles

Cited by

References

    1. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005;5:582–594. - PubMed
    1. Hariharan S. BK virus nephritis after renal transplantation. Kidney Int. 2006;69:655–662. - PubMed
    1. Ramos E, Hirsch HH. Polyomavirus-associated nephropathy: updates on a persisting challenge. Transpl Infect Dis. 2006;8:59–61. - PubMed
    1. Hirsch HH, Randhawa P AST Infectious Disease Community of Practice. BK virus in solid organ transplant recipients. Am J Transplant. 2009;9:S136–S146. - PubMed
    1. Binet I, Nickeleit V, Hirsh HH, et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation. 1999;67:918–922. - PubMed

Publication types

MeSH terms